Cytosorbents Corp Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cytosorbents Corporation on August 12, 2021. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol CTSO. The filing reports a significant regulatory milestone regarding the Company's DrugSorb-ATR Antithrombotic Removal System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance data.
Material Changes
On August 12, 2021, the Company announced it received a second Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its DrugSorb-ATR Antithrombotic Removal System. This designation is intended to facilitate the development and expedite the review of devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the regulatory designation. The primary focus is the incorporation of the press release (Exhibit 99.1) detailing the FDA announcement.
Key Facts for Investor Verification
- Verify the specific criteria and implications of the FDA Breakthrough Device designation for the DrugSorb-ATR system.
- Review the attached press release (Exhibit 99.1) for details on the intended use and clinical status of the device.
- Confirm the Company's current cash position and runway in separate financial filings (e.g., 10-Q or 10-K) as this 8-K contains no financial data.
- Monitor future filings for updates on the regulatory review timeline resulting from this designation.